SID&GP signs a cooperation agreement with PharmaPharm

| By | Pharmaceutical Industry, PharmaPharm, SID&GP

On November 14, 2018, the State Institute of Drugs and Good Practices (SID & GP) signed a cooperation agreement with the integrated pharmaceutical portal PharmaPharm within the framework of Life Sciences Invest in St. Petersburg.

The signing took place within the framework of the discussion session dedicated to Transition to a common EAEU market drug circulation that was chaired by Vladislav Shestakov, Director of the State Institute of Drugs and Good Practices.

The mission of the portal is to create an integrated expert platform for effective interaction of all stakeholders of the pharmaceutical community, which in turn will benefit industry as a whole. Cooperation with the FSI ‘SID & GP’ will allow sharing genuine materials of the institute’s leading experts, information exchange, implementation of joint activities and programs, maximum mutually beneficial support for successful association and development of the pharmaceutical community.

Zakhar Golant, Board Chairman of the Russian Union of Pharmaceutical and Biomedical Cluster, commented:

“A great number of regulatory issues require professional discussion of experts. Over the past 6-7 years of active growth in the industry, discussions have taken place in the format of many different conferences; most of them – however – leave many questions unanswered. There is a need for an online platform that could guarantee a sufficient number of expert discussions without distracting specialists from work.”

The mission of the integrated pharmaceutical portal is to strengthen the expert community by bringing together professionals from all sectors of the industry at one site. Involvement of leading professionals make it possible for the portal to focus on in-depth expertise of industry specific issues.

Anna Plesovskikh, PharmaPharm Managing Partner, stated:

“I consider partnership agreements to be an important step on the road towards unification of the pharmaceutical community, and I am very pleased that the State Institute of Drugs and Good Practices is our first partner. We have worked together from the very concept of the pharmaceutical portal, literally from scratch. Also, at Life Sciences Invest, we plan to sign agreements with the Biomedical Cell Products Association, as well as with the Russian Union of Pharmaceutical and Biomedical Cluster.”

PharmaPharm plans to present a unique analytics from Russian and foreign experts. All significant events will be addressed on the forum and reflected in the expert materials. Opportunities to seek answers from particular categories of experts will increase information outreach on urgent issues and make the community more transparent and open, and – consequently – more effective.

Vladislav Shestakov, Director of the State Institute of Drugs and Good Practices, said:

“It is very important to be constantly available for pharmaceutical manufacturers, timely provide relevant clarifications on all GMP-related issues and other expertise of the institute. Consequently, a position of transparency and accessibility is the most correct way for competent and productive interaction of all industry stakeholders.”

SOURCE: sid&gp
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.